Chiropractors in Mcfarland, WI Accepting Medicare
5 Chiropractors found. Showing 1 - 5
 Realign Family Chiropractic, Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 4877 Larson Beach Rd, Mcfarland, WI 53558 Phone: 608-921-8830 |
 Dr. Kim R Robb, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5708 Highway 51, Mcfarland, WI 53558 Phone: 608-838-3600 |
 Dr. Ann Marie Metzler, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 4861 Larson Beach Rd, Zelm Chiropractic Center Sc, Mcfarland, WI 53558 Phone: 608-838-7723 Fax: 608-838-6379 |
Dr. Kaitlyn Flamand, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 4861 Larson Beach Rd, Mcfarland, WI 53558 Phone: 262-951-6414 |
Sarah Nelson Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 4861 Larson Beach Rd, Mcfarland, WI 53558 Phone: 608-838-7723 Fax: 608-838-6379 |
News Archive
'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes
Parents found to be carriers of a mutated form of the tumor suppressor genes known as BRCA1 and BRCA2 do not always share these test results with their children, but they may choose to discuss related information important to their own health with them. That is the result of a study conducted by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues, whose findings suggest that those parents are using the discovery of their mutation status as an opportunity for a "teachable moment" in educating their offspring about cancer risk reduction.
Scientists develop new technique to analyze bacterial populations
Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens.
Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients
Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.
Beta blockers can reduce risk of Alzheimer's, other types of dementia
People taking the blood pressure drugs called beta blockers may be less likely to have changes in the brain that can be signs of Alzheimer's disease and other types of dementia, according to a study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.
› Verified 7 days ago